Elyse Julian, DO
Dermatology · Plantation, FLNPI 1851743587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,696, 3.4 times the $1,085 reported in 2019.
Across 479 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sanofi$1K
- Lilly USA, LLC$856
- Regeneron Healthcare Solutions, Inc.$809
- Organogenesis Inc.$734
- Biofrontera Inc.$682
- plus $5K from 27 others
Across 12 payments — averaging $26,936 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$305K
- Sanofi Pasteur Inc.$18K
What the payments were for
- Speaking & faculty fees$3503%
- Food & beverage$10,32494%
- Education$3243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,622 |
| Sanofi | 50 | $1,400 |
| Lilly USA, LLC | 35 | $856 |
| Regeneron Healthcare Solutions, Inc. | 28 | $809 |
| Organogenesis Inc. | 32 | $734 |
| Biofrontera Inc. | 13 | $682 |
| Johnson & Johnson | 26 | $666 |
| Pfizer | 37 | $661 |
| LEO Pharma Inc. | 27 | $459 |
| Novartis | 20 | $413 |
| Incyte Corporation | 15 | $393 |
| UCB, Inc. | 15 | $381 |
| Galderma Laboratories, L.p. | 21 | $262 |
| Strata Skin Sciences, Inc. | 25 | $251 |
| Sun Pharmaceutical Industries Inc. | 11 | $241 |
| Amgen | 10 | $227 |
| Revance Therapeutics, Inc. | 4 | $225 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $142 |
| Arcutis Biotherapeutics, Inc. | 5 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Verrica Pharmaceuticals Inc. | 3 | $66 |
| Botanix SB Inc | 3 | $57 |
| VYNE Pharmaceuticals Inc. | 2 | $43 |
| Mayne Pharma Commercial LLC | 2 | $38 |
| Almirall LLC | 2 | $36 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $29 |
| Cipher Pharmaceuticals US LLC | 1 | $26 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $17 |
| Organon | 2 | $13 |
| Dermira, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMELUZ$475
- BF-RhodoLED$475
- XEPI$475
- DUPIXENT$118
- DAXXIFY$108
How this compares
$10,998 in reported general payments places this provider in the 80th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 26 | $105,584 |
| Humira(Cf) PenAdalimumab | 12 | $85,564 |
| Clobetasol Propionate | 92 | $3,263 |
| Ketoconazole | 215 | $2,971 |
| Tacrolimus | 17 | $2,112 |
| Fluocinolone Acetonide | 16 | $938 |
| Metronidazole | 17 | $871 |
| Ciclopirox | 30 | $765 |
| Tretinoin | 18 | $756 |
| Triamcinolone Acetonide | 112 | $684 |
| ValacyclovirValacyclovir Hcl | 23 | $654 |
| Mometasone Furoate | 27 | $494 |
| Doxycycline Hyclate | 45 | $488 |
| Mupirocin | 69 | $374 |
| Nystatin | 25 | $320 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Plantation
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.